Correlato neurobiológico de los síntomas premotores del parkinson: el origen en la teoría de Braak
Barra lateral del artículo
Descargas
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Contenido principal del artículo
Resumen
El diagnóstico de enfermedad de Parkinson (ED) se basa en las principales manifestaciones motoras: bradicinesia en combinación con temblor en reposo, rigidez o ambos. Cuando se realiza el diagnóstico basado en la sintomatología motora clínica típica ya se han perdido hasta el 60 % de las neuronas dopaminérgicas de la sustancia negra pars compacta mesencefálica. La identificación de los síntomas premotores son un marcador temprano para sospechar la aparición futura de la enfermedad, así como su progresión y gravedad. La hipótesis sobre la patogénesis que mejor expone la progresión de la enfermedad es la teoría de Braak. Esta se basa en la aparición y presencia de cuerpos de Lewy en diferentes estructuras anatómicas, las cuales representadas en cada uno de sus seis estadios y podrían ser la explicación biológica de los síntomas premotores, motores y no motores. La detección temprana de los síntomas premotores puede tener repercusiones positivas en el enfoque, seguimiento, diagnóstico y tratamiento de la EP. El propósito de este artículo es identificar las aproximaciones neurológicas descritas por la teoría de Braak para los síntomas premotores de la enfermedad de Parkinson de acuerdo con la literatura publicada en los últimos 20 años.
Citas
Rietdijk C, Perez-Pardo P, Garssen J, van Wezel R, Kraneveld A. Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol. 2017;8:37.
Opara JA, Brola W, Leonardi M, Błaszczyk B. Quality of life in Parkinson’s disease. J Med Life. 2012;5(4):375-81.
Poewe W, Seppi K, Tanner C. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013 (2017).
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-2303.
Zis P, Erro R, Walton CC, Sauerbier A, Chaudhuri KR. The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: A state-of-the-art systematic review. 2015;1:15013.
Mahlknecht P, Seppi K, Poewe W. The concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681–97.
Reichmann H. Premotor diagnosis of Parkinson’s disease. Neurosci Bull. 2017;33(5):526–34.
Rodríguez-Violante M, Zerón-Martínez R, Cervantes-Arriaga A, Corona T. Who can diagnose Parkinson’s disease first? Role of Pre-motor symptoms. Arch Med Res. 2017;48(3):221–7.
Thaler A, Alcalay RN. Diagnosis and medical management of Parkinson disease. CONTINUUM: Lifelong Learning in Neurology. 2022;28(5):1281–300.
Fullard ME, Morley JF, Duda JE. Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull. 2017;33(5):515–25.
Barber TR, Klein JC, Mackay CE, Hu MTM. Neuroimaging in pre-motor Parkinson’s disease. NeuroImage Clin. 2017;15:215–27.
Huang H, Xu H, Luo Q, He J, Li M, Chen H, et al. Fecal microbiota transplantation to treat Parkinson’s disease with constipation: A case report. Med (United States). 2019;98(26):1-4.
Vegas-Suarez S, Paredes-Rodriguez E, Aristieta A, Lafuente JV, Miguelez C, Ugedo L. Dysfunction of serotonergic neurons in Parkinson’s disease and dyskinesia. International Review of Neurobiology [Internet]. 2019;146:259-279. Disponible en: http://dx.doi.org/10.1016/bs.irn.2019.06.013
McCann H, Cartwright H, Halliday GM. Neuropathology of α-synuclein propagation and braak hypothesis. Mov Disord. 2016;31(2):152–60.
Visanji N, Marras C. The relevance of pre-motor symptoms in Parkinsons disease. Expert Rev Neurother. 2015;15(10):1205–17.
Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: The dual syndrome hypothesis. Neurodegener Dis. 2012;11(2):79–92.
Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol. 2014 Aug;27(4):434–41.
Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson’s disease: A longitudinal 123I-FP-CIT SPECT study. Park Relat Disord [Internet]. 2020;77:170–5.
Pellegrini C, Antonioli L, Colucci R, Ballabeni V, Barocelli E, Bernardini N, et al. Gastric motor dysfunctions in Parkinson’s disease: Current pre-clinical evidence. Park Relat Disord. 2015;21(12):1407–14.
Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord. 2006;21(12):2062-7.
Kim S, Kwon SH, Kam TI, Panicker N, Karuppagounder SS, Lee S, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103(4):627-641.e7.
Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: Another vulnerability target in Parkinson’s disease. Mov Disord. 2019;34(10):1423–9.
Stefani A, Högl B. Sleep in Parkinson’s disease. Neuropsychopharmacology. 2020;45(1):121-128.
Surmeier DJ. Determinants of dopaminergic neuron loss in Parkinson’s disease. FEBS J. 2018;285(19):3657-3668.
Poston KL, Cruadhlaoich MA, Santoso LF, Bernstein JD, Liu T, Wang Y, et al. Substantia nigra volume dissociates bradykinesia and rigidity from tremor in Parkinson’s disease: A 7 tesla imaging study. J Parkinsons Dis. 2020;10(2):591-604.
Zach H, Dirkx MF, Roth D, Pasman JW, Bloem BR, Helmich RC. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020;95(11):E1461–70.
Hallett M. Parkinson’s disease tremor: Pathophysiology. Park Relat Disord. 2012;18:S85–6.
Rong S, Li Y, Li B, Nie K, Zhang P, Cai T, et al. Meynert nucleus-related cortical thinning in Parkinson’s disease with mild cognitive impairment. Quant Imaging Med Surg. 2021;11(4):1554-1566.
Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13(4):217–31.
Salzman CD, Fusi S. Emotion, cognition, and mental state representation in amygdala and prefrontal cortex. Annu Rev Neurosci. 2010;33:173-202.
Hanagasi HA, Tufekcioglu Z, Emre M. Dementia in Parkinson’s disease. J Neurol Sci. 2017;374(2016):26–31.
Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.e5.
Hirayama M, Ohno K. Parkinson’s disease and gut microbiota. Ann Nutr Metab. 2021;77:28-35.
Stocchi F, Torti M. Constipation in Parkinson’s disease. International Review of Neurobiology [Internet]. 2017;134:811-826 p. Disponible en: http://dx.doi.org/10.1016/bs.irn.2017.06.003
Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24.
Jellinger KA. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm (Vienna). 2019;126(4):423-431.
Li J, Gu CZ, Su JB, Zhu LH, Zhou Y, Huang HY, et al. Changes in olfactory bulb volume in Parkinson’s disease: A systematic review and meta-analysis. Plos One. 2016;11(2):e0149286.
Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson’s disease. Brain. 2006;129(Pt 2):538-42.
Tarakad A, Jankovic J. Anosmia and ageusia in Parkinson’s disease. Int Rev Neurobiol. 2017;133:541-556.
Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: How far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother. 2012;12(6):673-86.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th Ed., Text Revision. Washington, DC: American Psychiatric Association; 2022.
Bang Y, Lim J, Choi HJ. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: Clues to early diagnosis and effective treatment. Arch Pharm Res. 2021;44(6):588–604.
Shen CC, Tsai SJ, Perng CL, Kuo BIT, Yang AC. Risk of Parkinson disease after depression: A nationwide population-based study. Neurology. 2013;81(17):1538–44.
Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The onset of nonmotor symptoms in Parkinson’s disease (The ONSET PDStudy). Movement Disorders. 2015;30(2):229–37.
Depression [Internet]. [citado el 10 de septiembre de 2022]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/depression.
Menon B, Nayar R, Kumar S, Cherkil S, Venkatachalam A, Surendran K, et al. Parkinson’s disease, depression, and quality-of-life. Indian J Psychol Med. 2015;37(2):144–8.
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18(7):435–50.
Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Movement Disorders. 2013;28(5):597–604.
Isaacson S, Skettini J. Neurogenic orthostatic hypotension in Parkinson’s disease: Evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014;10:169-76.
Lamotte G, Lenka A. Orthostatic hypotension in Parkinson disease: What is new? Neurol Clin Pract. 2022;12(5):e112-e115.
Palma JA, Kaufmann H. Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:S94-8.
Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T. SPECT imaging of the dopamine transporter with [123I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson’s disease with urinary dysfunction. J Neurol Sci. 2001;187(1–2):55–9.
Picillo M, Palladino R, Barone P, Erro R, Colosimo C, Marconi R, et al. The PRIAMO study: Urinary dysfunction as a marker of disease progression in early Parkinson’s disease. Eur J Neurol.
;24(6):788–95.
Hasan S, Mielke MM, Ahlskog JE, Bower J, Turcano P, Savica R. Erectile dysfunction preceding clinically diagnosed α -synucleinopathies: A case-control study in Olmsted County. Parkinsons Dis. 2019;2019:1–6.
Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: A prospective study. Brain. 2019;142(7):2051-2067.
Shen Y, Liu CF. Sleep disorders in Parkinson’s disease: Present status and future prospects. Chin Med J (Engl). 2018;131(8):883-885.
Kim YE, Jeon BS. Clinical implication of REM sleep behavior disorder in Parkinson’s disease. J Parkinsons Dis. 2014;4(2):237-44.
Sateia MJ. International classification of sleep disorders-third edition: Highlights and modifications. Chest. 2014;146(5):1387-1394.
Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 2015;138(10):2964–73.
Taddei RN, Cankaya S, Dhaliwal S, Chaudhuri KR. Management of psychosis in Parkinson’s disease: Emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinsons Dis. 2017;2017:1–18.
Reich A, Kwiatkowska D, Pacan P. Delusions of parasitosis: An Update. Dermatol Ther (Heidelb). 2019;9(4):631–8.
Torales J, García O, Barrios I, O’Higgins M, Castaldelli‐Maia JM, Ventriglio A, et al. Delusional infestation: Clinical presentations, diagnosis, and management. J Cosmet Dermatol. 2020;19(12):3183–8.
Oh M, Kim JW, Lee SM. Delusional parasitosis as premotor symptom of Parkinson’s disease: A case report. World J Clin Cases. 2022;10(9):2858–63.